Lei, Nuo, and Nord will reduce the prices of weight loss drugs in exchange for a three-year tariff grace period from the US government.

Eli Lilly and Novo Nordisk reached an agreement with the Trump administration to significantly reduce the prices of their popular weight loss drugs in exchange for tariff exemptions and allowing more federal Medicare patients to access medication. According to senior government officials, US President Donald Trump announced on Thursday at the White House that a deal had been reached with Eli Lilly and Novo Nordisk, which will allow some federal Medicare beneficiaries to access some of the world's best-selling drugs. An official stated that these companies' products will be granted a three-year grace period, protected from any future tariffs on drug imports imposed by Trump. This is similar to the terms reached in previous drug pricing agreements with pharmaceutical industry competitors.